1. Smucny J. Evaluation of the patient with dyspepsia. J Fam Pract 2001;50:583-542.

2. Flynn CA. Evaluation and treatment of adults with gastro-esophageal reflux disease. J Fam Pract 2001;50:57-63.

3. Jones R, Tate C, Sladen G, Weston-Baker J. A trial of test-and-treat strategy for Helicobacter pylori positive dyspeptic patients in general practice. Intern J Clin Pract 1999;53:413-16.

4. Ebell MH, Warbasse L, Brenner C. Evaluation of the dyspeptic patient: a cost utility study. J Fam Pract 1997;44:545-55.

5. Kurata J, Nogawa A. Meta-analysis of risk factors for peptic ulcer: nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking. J Clin Gastroenterol 1997;24:2-17.

6. Graham DY. Nonsteriodal anti-inflammatory druge, Helicobacter pylori, and ulcers: where we stand. Am J Gastroenterol 1996;91:2080-86.

7. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000;160:2093-99.

8. Rostom A, Wells G, Tugwell P, Welch V, Dube C, McGowan J. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database of Systematic Reviews 2001; Issue 1.

9. Laine L, Harper S, Simon T, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 1999;117:776-83.

10. Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-933.

11. Goldstein JL, Silverstein FE, Agrawal NM, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000;95:1681-690.

12. Veldhuyzen van Zanten SJ, Flook N, et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Can Med Assoc J 2000;162(suppl 12):S3-S23.

13. Peterson WL, Fendrick AM, Cave DR, Peura DA, Garabedian-Raffalo S, Laine L. Helicobacter pylori-related disease: guidelines for testing and treatment. Arch Intern Med 2000;160:1285-291.

14. Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996;110:1244-252.

15. Laine L, Hopkins RJ, Girardi L. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the Unites States been overstated? A meta-analysis of rigourously designed trials. Amer J Gastroenterol 1998;93:1409-415.

16. Megraud F. Resistance of Helicobacter pylori to antibiotics: the main limitation of current proton-pump inhibitor triple therapy. Eur J Gastroenterol Hepatol 1999;11(suppl 2):S35-S37.

17. Graham DY, Lew GM, Malaty HM, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992;102:493-96.

18. Rene W.M., van der Hulst RWM, Keller JJ, Rauws EA, Tytgat G. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter 1996;1:6-18.

19. Graham D Y. Highlights from 100th Annual Meeting of the American Gastroenterological Association and Digestive Disease Week. Helicobacter Today 1999;6:1-24.

20. Laine L, Estrada R, Trujillo M, Emami S. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori. Am J Gastroenterol 1997;92:2213-215.

21. De Wit NJ, Quartero AO, Numans ME. Helicobacter pylori treatment instead of maintenance therapy for peptic ulcer disease: the effectiveness of case-finding in general practice. Aliment Pharmacol Ther 1999;13:1317-321.

22. Wong BC, Lam SK, Lai KC, et al. Triple therapy for Helicobacter pylori eradication is more effective than long-term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study. Aliment Pharmacol Ther 1999;13:303-09.

23. Laine L, Estrada R, Trujillo M, Knigge K, Fennerty MB. Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann Intern Med 1998;129:547-50.

24. Soo S, Moayyedi P, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for nonulcer dyspepsia. Cochrane Database of Systematic Reviews 2001; Issue 1.

25. Jaakkimainen RL, Boyle E, Tudiver F. Is Helicobacter pylori associated with non-ulcer dyspepsia and will eradication improve symptoms? A meta-analysis [see comments]. BMJ 1999;319:1040-44.

26. Veldhuyzen van Zanten SJ, Cleary C, et al. Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Amer J Gastroenterol 1996;91:660-73.

27. Laine L, Ahnen D, McClain C, Solcia E, Walsh JH. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2000;14:651-68.

28. Jackson JL, O’Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Amer J Med 2000;108:65-72.

29. Laine L, Schoenfeld P, Fennerty MB. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia: a meta-analysis of randomized, controlled trials. Ann Intern Med 2001;134:361-69.

30. Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database of Systematic Reviews 2001; Issue 1.

31. Mohammed Z, Abu-Mahfouz MD, Prasad VM, Santogade P, Cutler AF. Helicobacter pylori recurrence after successful eradication: 5-year follow-up in the United States. Am J Gastroenterol 1997;11:2025-28.

32. Kepekci Y, Kadayifci A. Does the eradication of Helicobacter pylori cure duodenal ulcer disease in communities with a high prevalence rate? Comparison with long-term acid suppression. Int J Clin Pract 1999;53:505-8.

33. Scheiman JM, Cutler AF. Helicobacter pylori and gastric cancer. Am J Med 1999;106:222-26.

34. Rupnow MF, Owens DK, Shachter R, Parsonnet J. Helicobacter pylori vaccine development and use: a cost-effectiveness analysis using the Institute of Medicine Methodology. Helicobacter 1999;4:272-80.

35. Laine L, Estrada R, Fukanaga K, Neil G. Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori. Aliment Pharmacol Ther 1996;10:1029-33.

36. Yousfi MM, El-Zimaity HMT, Al-assi MT, Cole RA, Genta RM, Graham DY. Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1995;9:209-12.

37. de Boer WA, Driessen W, Jansz A, Tytgat G. Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet 95 A.D.;345:817-820.

38. Hansen JM, Bytzer P, Schaffalitzky de Muckadell OB. Placebo-controlled trial of cisapride and nizatidine in unselected patients with functional dyspepsia. Am J Gastroenterol 1998;93:368-74.

James A. McHugh, MD

Article

Chronic hepatitis B infection: A workshop consensus statement and algorithm